Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System

NCT ID: NCT00528385

Last Updated: 2007-09-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-03-31

Brief Summary

The main purpose of the study is find whether the addition of aldosterone antagonist, spironolactone to dual renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction of proteinuria, main prognostic marker of chronic kidney disease progression.

Detailed Description

The renin-angiotensin-aldosterone system (RAAS) plays an important role in the progression of chronic kidney diseases (CKD), and inhibition of the RAAS with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) may retard CKD progression. Dual pharmacological blockade of the RAAS with ACEI and ARB is recommended as a standard renoprotective management at least in patients with nondiabetic proteinuric CKD. However, neither ACEI nor ARB, even in high doses or in concomitant usage, abrogate the progression of CKD completely. Innovative approaches are needed to keep patients with CKD off dialysis. Additional blockade of the aldosterone pathway may prove to be such beneficial therapeutic concept.Aldosterone, a final effector of RAAS plays a significant role in the pathogenesis of CKD independently of angiotensin II through direct cellular action. This includes promoting an inflammatory response, endothelial dysfunction, and fibrosis by increasing plasminogen activator inhibitor (PAI-1) and transforming growth factor beta-1 (TGF-beta-1) expression and stimulation reactive oxygen species.A number of observations suggest nongenomic vasoconstrictor action of aldosterone leading to raise arterial and glomerular capillary pressure.Given these facts additional administration of aldosterone antagonist to combination treatment with ACEI and ARB, so called triple RAAS blockade may provide additional renal protection. To shed more light on this issue, we performed a randomised open controlled study to evaluate the influence of triple RAAS therapy on surrogate markers of kidney injury, i.e. proteinuria, markers of tubular involvement and kidney fibrosis.

Conditions

Chronic Kidney Disease; Proteinuria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Spironolactone (Spironol) 25 mg

In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• chronic kidney disease
• stable proteinuria above 300 mg/24 hours (no variations above 25% in the last 6 months)
• normal or slightly impaired stable renal function defined as serum creatinine level below 1.7 mg/dl (eGFR > 45 ml/min)

Exclusion Criteria

• nephrotic syndrome
• steroids or other immunosuppressive treatment minimum during six months before the study
• diabetes mellitus
• potassium serum level > 5.1 mEq/L
• albumin serum level < 2.0mg/dL
• creatinine serum level >2 mg/dl
• current diagnosis of heart failure New York Heart Association (NYHA) Class II-IV
• clinically significant valvular heart disease or second or third degree heart block without a pacemaker
• history of hypertensive encephalopathy, cerebrovascular accident or transient ischemic cerebral attack
• history of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention
• history of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years
• pregnant or nursing women
• any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs.
• history of alcohol abuse
• NSAID abuse (more than 2 doses per week)
• known or suspected contraindications to the study medications, including history of allergy to ACE inhibitors, AT-1 receptor blockers and aldosterone antagonists

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical University of Gdansk

OTHER

Sponsor Role: lead

Principal Investigators

Boleslaw Rutkowski, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Nephrology Transplantology and Internal Medicine. Medical University of Gdansk.

References

Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.

Reference Type: DERIVED

PMID: 37466151 (View on PubMed)

Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.

Reference Type: DERIVED

PMID: 33107592 (View on PubMed)

Other Identifiers

ST-4/RAAS/02

Identifier Type: -

Identifier Source: org_study_id